口服前列腺素治疗肺动脉高压研究进展
Research progress on oral prostaglandin in the treatment of pulmonary hypertension
李义 1伍广伟 1朱海通 1黄梦怡1
作者信息
- 1. 广西壮族自治区人民医院心血管内科,广西南宁 530016
- 折叠
摘要
肺动脉高压(pulmonary arterial hypertension,PAH)是一种进行性的、治愈难度大的疾病,其特征为肺小动脉的收缩与重塑,同时伴肺动脉压力增加.随着PAH进展,右心室负荷增加,最终发展为心力衰竭(heart failure).口服前列腺素(prostaglandin,PG)及其类似物能改善PAH临床症状、降低恶化/死亡风险、延缓疾病进展,且相对安全、方便,患者依从性高.现对口服PG治疗PAH机制及应用相关文献进行综述,为临床提供决策依据.
Abstract
Pulmonary arterial hypertension(PAH)is a progressive and treatable disease characterized by contraction and remodeling of pulmonary arteriole accompanied by increased pulmonary arterial pressure.As PAH progresses,the load on the right ventricle increases,eventually leading to heart failure.Oral prostaglandin(PG)and their analogues can improve the clinical symptoms of PAH,reduce the risk of deterioration or death,delay disease progression,and are relatively safe,convenient,and have high patient compliance.This article reviewed the mechanism and application of oral PG in the treatment of PAH and provided a basis for clinical application.
关键词
口服前列腺素/肺动脉高压/曲前列环素/贝前列腺素/司来帕格/雷利帕格Key words
oral prostaglandin/pulmonary arterial hypertension/troprostacycline/bayprostaglandin/selexipag/ralinepag引用本文复制引用
出版年
2024
NETL
NSTL
万方数据